LA JOLLA, CA, June 22, 2022 (GLOBE NEWSWIRE) – MediciNova, Inc. , a biopharmaceutical firm traded on the NASDAQ International Market (Nasdaq: MNOV) and the JASDAQ Market on the Tokyo Inventory Alternate (code quantity: 4875), introduced as we speak that it’ll start a complete analysis collaboration with Juntendo College, Faculty of Medication (2-1-1 Hongo, Bunkyo- ko, Tokyo, Japan) to judge the mechanism of motion of MN-001 (tipilukast) on lipid metabolism and the metabolic syndrome.
The principal collaborator is Takashi Mitsui, MD, PhD, professor and chair of the Division of Laboratory Medication, a well known knowledgeable in lipid metabolism and a specialist in dyslipidemia and metabolic syndrome.
Kazuko Matsuda, MD, Ph.D. MD, MPH, Chief Medical Officer of MediciNova, Inc, mentioned: “MN 001 is a novel orally administered compound with a number of mechanisms, and its anti-inflammatory and anti inflammatory results have been noticed in research of a number of animal fashions. It has additionally been noticed to scale back triglyceride ranges in Blood for sufferers with elevated serum triglycerides in a number of beforehand performed scientific trials.In a section II trial in hyperlipidemic NASH/NAFLD sufferers, MN-001 (Teblocast) lowered serum triglycerides, elevated excessive lipoproteins HDL-C, and low-density lipoprotein (LDL) decreases in the course of the 12-week remedy interval.Moreover, enhancements in blood lipid profile had been extra vital in sufferers with kind 2 diabetes/prediabetes. We consider this analysis collaboration will present new insights into the mechanism of motion of MN-001 within the space of lipid metabolism and metabolic syndrome and determine situations which will profit from MN-001 remedy.”
About MN-001 (Teblocast)
MN-001 (tipilukast) is a novel, oral bioavailable small molecule compound that’s believed to exert its results via a number of mechanisms to provide its anti-inflammatory and antifibrotic exercise in preclinical fashions, together with leukotriene receptor (LT) antagonism, and phosphodiesterase (PDE) inhibition ( Primarily 3 and 4), and 5-lipoxygenase (5-LO) is inhibited. The 5-LO/LT pathway has been postulated as a pathogenic issue within the improvement of fibrosis, and the inhibitory impact of MN-001 on the 5-LO pathway and the 5-LO/LT pathway is a brand new strategy to the remedy of fibrosis. MN-001 has been proven to downregulate the expression of fibrosis-promoting genes together with LOXL2, Collagen Kind 1 and TIMP-1. MN-001 has additionally been proven to downregulate the expression of inflammation-promoting genes together with CCR2 and MCP-1. As well as, MN-001 was discovered to inhibit the synthesis of triglycerides in hepatocytes by inhibiting the uptake of arachidonic acid.
MediciNova, Inc. is a clinical-stage biopharmaceutical firm that’s growing an intensive late-stage pipeline of novel small-molecule therapies for inflammatory, fibrotic and neurodegenerative ailments. Primarily based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with a number of mechanisms of motion and robust security profiles, MediciNova has 11 applications in scientific improvement. MediciNova’s important guardian, MN-166 (ibudilast), is presently in stage 3 for amyotrophic lateral sclerosis (ALS) and cervical myelofibrosis (DCM) and is prepared for stage 3 for progressive a number of sclerosis (MS). MN-166 (ibudilast) has been studied in a section II trial in sufferers in danger for acute respiratory misery syndrome (ARDS) and can be being evaluated in section II trials in glioblastoma and substance dependence. MN-001 (Teblocast) has been evaluated in a Section II trial in idiopathic pulmonary fibrosis (IPF) and is in preparation for a Section II trial in nonalcoholic fatty liver illness (NAFLD). MediciNova has a confirmed observe report of securing investigator-sponsored scientific trials funded by authorities grants.
Statements on this press launch that aren’t historic in nature represent forward-looking statements inside the which means of the protected harbor provisions of the Personal Securities Litigation Reform Act of 1995. These forward-looking statements embody, however are usually not restricted to, statements relating to the longer term improvement and effectiveness of MN-166 and MN- 001, MN-221 and MN-029. Such forward-looking statements could also be preceded, adopted by, or in any other case included the phrases “believes,” “expects,” “expects,” “intends,” “estimates,” “tasks,” “may,” “will,” “would,” “consideration”, “planning” or comparable expressions. These forward-looking statements contain quite a lot of dangers and uncertainties that might trigger precise outcomes or occasions to vary materially from these expressed or implied by these forward-looking statements. Elements that might trigger them to vary embody: Precise outcomes or occasions materially completely different from these expressed or implied in these forward-looking statements embody, however are usually not restricted to, the dangers of acquiring a future companion or grant financing to develop MN-166, MN-001, MN-221 and MN-029 and the dangers elevate adequate capital when wanted to fund MediciNova’s operations and contribute to scientific improvement and the dangers and uncertainties inherent in scientific trials, together with the potential value, anticipated timing, and dangers related to scientific trials designed to satisfy FDA steerage and scalability for additional improvement contemplating these components, and product improvement and commercialization dangers, uncertainty n relating to whether or not scientific trial outcomes will likely be predictive of outcomes at later levels of product improvement, the danger of delay or failure to acquire or preserve regulatory approval, the dangers related to counting on third events to sponsor and fund scientific trials, and dangers associated to mental property rights lectured in merchandise the candidate and the power to defend and implement such mental property rights, the danger of failure of third events that MediciNova depends on to conduct their scientific trials and manufacture its Candidate Merchandise to work as anticipated, the danger of elevated value and delays resulting from delays in initiating, recording, finishing or analyzing scientific trials or vital points Associated to the adequacy of scientific trial designs or implementation of scientific trials, timing of anticipated submitting with regulatory authorities, MediciNova collaboration with third events, availability of funds to finish product improvement plans and MediciNova’s means to acquire third-party funding for applications and lift adequate capital when wanted, different dangers and uncertainties recognized On MediciNova’s filings with the Securities and Alternate Fee, together with its annual report on Kind 10-Ok for the yr ended December 31, 202 1 and its subsequent periodic reviews on Kind 10-Q and present reviews on Kind 8-Ok. You shouldn’t place undue reliance on these forward-looking statements, which communicate solely as of the date of this announcement. MediciNova disclaims any intention or obligation to revise or replace these forward-looking statements.
Contact the investor: